BASTIDE LE CONFORT MEDICAL (BLC.PA) Fundamental Analysis & Valuation

EPA:BLC • FR0000035370

Current stock price

24 EUR
+0.15 (+0.63%)
Last:

This BLC.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. BLC.PA Profitability Analysis

1.1 Basic Checks

  • BLC had positive earnings in the past year.
  • BLC had a positive operating cash flow in the past year.
  • Of the past 5 years BLC 4 years were profitable.
  • Each year in the past 5 years BLC had a positive operating cash flow.
BLC.PA Yearly Net Income VS EBIT VS OCF VS FCFBLC.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M 60M 80M 100M

1.2 Ratios

  • BLC has a better Return On Assets (5.07%) than 89.66% of its industry peers.
  • BLC's Return On Equity of 28.66% is amongst the best of the industry. BLC outperforms 100.00% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 6.83%, BLC is in the better half of the industry, outperforming 75.86% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for BLC is in line with the industry average of 5.99%.
  • The last Return On Invested Capital (6.83%) for BLC is above the 3 year average (6.14%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 5.07%
ROE 28.66%
ROIC 6.83%
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.21%
ROIC(3y)6.14%
ROIC(5y)5.72%
BLC.PA Yearly ROA, ROE, ROICBLC.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 10 15

1.3 Margins

  • BLC has a Profit Margin of 6.19%. This is amongst the best in the industry. BLC outperforms 93.10% of its industry peers.
  • BLC's Profit Margin has declined in the last couple of years.
  • The Operating Margin of BLC (8.05%) is better than 62.07% of its industry peers.
  • In the last couple of years the Operating Margin of BLC has remained more or less at the same level.
  • Looking at the Gross Margin, with a value of 67.32%, BLC is in the better half of the industry, outperforming 72.41% of the companies in the same industry.
  • In the last couple of years the Gross Margin of BLC has grown nicely.
Industry RankSector Rank
OM 8.05%
PM (TTM) 6.19%
GM 67.32%
OM growth 3Y5.49%
OM growth 5Y0.75%
PM growth 3Y-66.74%
PM growth 5Y-48.72%
GM growth 3Y1.15%
GM growth 5Y6.69%
BLC.PA Yearly Profit, Operating, Gross MarginsBLC.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. BLC.PA Health Analysis

2.1 Basic Checks

  • BLC has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • BLC has about the same amout of shares outstanding than it did 1 year ago.
  • BLC has about the same amout of shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, BLC has an improved debt to assets ratio.
BLC.PA Yearly Shares OutstandingBLC.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M
BLC.PA Yearly Total Debt VS Total AssetsBLC.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • Based on the Altman-Z score of 1.53, we must say that BLC is in the distress zone and has some risk of bankruptcy.
  • BLC has a Altman-Z score (1.53) which is in line with its industry peers.
  • BLC has a debt to FCF ratio of 14.03. This is a negative value and a sign of low solvency as BLC would need 14.03 years to pay back of all of its debts.
  • BLC has a worse Debt to FCF ratio (14.03) than 62.07% of its industry peers.
  • BLC has a Debt/Equity ratio of 2.95. This is a high value indicating a heavy dependency on external financing.
  • BLC has a worse Debt to Equity ratio (2.95) than 72.41% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.95
Debt/FCF 14.03
Altman-Z 1.53
ROIC/WACC1.3
WACC5.26%
BLC.PA Yearly LT Debt VS Equity VS FCFBLC.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

2.3 Liquidity

  • BLC has a Current Ratio of 1.16. This is a normal value and indicates that BLC is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Current ratio value of 1.16, BLC perfoms like the industry average, outperforming 58.62% of the companies in the same industry.
  • BLC has a Quick Ratio of 1.16. This is a bad value and indicates that BLC is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.92, BLC is in line with its industry, outperforming 58.62% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.16
Quick Ratio 0.92
BLC.PA Yearly Current Assets VS Current LiabilitesBLC.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. BLC.PA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 1718.18% over the past year.
  • Measured over the past years, BLC shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -46.37% on average per year.
  • BLC shows a small growth in Revenue. In the last year, the Revenue has grown by 0.77%.
  • BLC shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.12% yearly.
EPS 1Y (TTM)1718.18%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%4912.5%
Revenue 1Y (TTM)0.77%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%-5.5%

3.2 Future

  • Based on estimates for the next years, BLC will show a small growth in Earnings Per Share. The EPS will grow by 5.90% on average per year.
  • BLC is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.69% yearly.
EPS Next Y-12.23%
EPS Next 2Y-1.23%
EPS Next 3Y5.9%
EPS Next 5YN/A
Revenue Next Year4.14%
Revenue Next 2Y4.76%
Revenue Next 3Y5.03%
Revenue Next 5Y7.69%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BLC.PA Yearly Revenue VS EstimatesBLC.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
BLC.PA Yearly EPS VS EstimatesBLC.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0.5 1 1.5 2 2.5

More info and screens

Find the best growth stocksShow best growing peers

6

4. BLC.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 6.00, which indicates a rather cheap valuation of BLC.
  • Based on the Price/Earnings ratio, BLC is valued cheaply inside the industry as 96.55% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 25.60. BLC is valued rather cheaply when compared to this.
  • With a Price/Forward Earnings ratio of 11.71, the valuation of BLC can be described as very reasonable.
  • BLC's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. BLC is cheaper than 72.41% of the companies in the same industry.
  • BLC is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.84, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 6
Fwd PE 11.71
BLC.PA Price Earnings VS Forward Price EarningsBLC.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • 93.10% of the companies in the same industry are more expensive than BLC, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of BLC indicates a somewhat cheap valuation: BLC is cheaper than 68.97% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 7.66
EV/EBITDA 4.87
BLC.PA Per share dataBLC.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

  • The decent profitability rating of BLC may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.23%
EPS Next 3Y5.9%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BLC.PA Dividend Analysis

5.1 Amount

  • No dividends for BLC!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BLC.PA Fundamentals: All Metrics, Ratios and Statistics

BASTIDE LE CONFORT MEDICAL

EPA:BLC (4/2/2026, 7:00:00 PM)

24

+0.15 (+0.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-18
Earnings (Next)05-14
Inst Owners12.76%
Inst Owner ChangeN/A
Ins Owners1.63%
Ins Owner ChangeN/A
Market Cap176.88M
Revenue(TTM)476.02M
Net Income(TTM)29.45M
Analysts77.14
Price Target40.8 (70%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP0.52%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.68%
PT rev (3m)11.11%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-8.26%
EPS NY rev (3m)-26.24%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.26%
Valuation
Industry RankSector Rank
PE 6
Fwd PE 11.71
P/S 0.37
P/FCF 7.66
P/OCF 2.45
P/B 1.72
P/tB N/A
EV/EBITDA 4.87
EPS(TTM)4
EY16.67%
EPS(NY)2.05
Fwd EY8.54%
FCF(TTM)3.13
FCFY13.06%
OCF(TTM)9.79
OCFY40.79%
SpS64.59
BVpS13.94
TBVpS-12.19
PEG (NY)N/A
PEG (5Y)N/A
Graham Number35.42
Profitability
Industry RankSector Rank
ROA 5.07%
ROE 28.66%
ROCE 9.29%
ROIC 6.83%
ROICexc 7.28%
ROICexgc 14.48%
OM 8.05%
PM (TTM) 6.19%
GM 67.32%
FCFM 4.85%
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.21%
ROIC(3y)6.14%
ROIC(5y)5.72%
ROICexc(3y)6.57%
ROICexc(5y)6.12%
ROICexgc(3y)13.99%
ROICexgc(5y)12.76%
ROCE(3y)8.36%
ROCE(5y)7.81%
ROICexgc growth 3Y3.04%
ROICexgc growth 5Y-0.89%
ROICexc growth 3Y7.75%
ROICexc growth 5Y0.36%
OM growth 3Y5.49%
OM growth 5Y0.75%
PM growth 3Y-66.74%
PM growth 5Y-48.72%
GM growth 3Y1.15%
GM growth 5Y6.69%
F-Score7
Asset Turnover0.82
Health
Industry RankSector Rank
Debt/Equity 2.95
Debt/FCF 14.03
Debt/EBITDA 3.11
Cap/Depr 83.01%
Cap/Sales 10.3%
Interest Coverage 250
Cash Conversion 74.08%
Profit Quality 78.46%
Current Ratio 1.16
Quick Ratio 0.92
Altman-Z 1.53
F-Score7
WACC5.26%
ROIC/WACC1.3
Cap/Depr(3y)93.32%
Cap/Depr(5y)92.23%
Cap/Sales(3y)11.17%
Cap/Sales(5y)11.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1718.18%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%4912.5%
EPS Next Y-12.23%
EPS Next 2Y-1.23%
EPS Next 3Y5.9%
EPS Next 5YN/A
Revenue 1Y (TTM)0.77%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%-5.5%
Revenue Next Year4.14%
Revenue Next 2Y4.76%
Revenue Next 3Y5.03%
Revenue Next 5Y7.69%
EBIT growth 1Y3.06%
EBIT growth 3Y7.18%
EBIT growth 5Y5.9%
EBIT Next Year138.04%
EBIT Next 3Y38.82%
EBIT Next 5YN/A
FCF growth 1Y-31.71%
FCF growth 3Y107.15%
FCF growth 5Y33.43%
OCF growth 1Y-17.98%
OCF growth 3Y17.38%
OCF growth 5Y14.21%

BASTIDE LE CONFORT MEDICAL / BLC.PA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BASTIDE LE CONFORT MEDICAL?

ChartMill assigns a fundamental rating of 5 / 10 to BLC.PA.


Can you provide the valuation status for BASTIDE LE CONFORT MEDICAL?

ChartMill assigns a valuation rating of 6 / 10 to BASTIDE LE CONFORT MEDICAL (BLC.PA). This can be considered as Fairly Valued.


What is the profitability of BLC stock?

BASTIDE LE CONFORT MEDICAL (BLC.PA) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for BLC stock?

The Price/Earnings (PE) ratio for BASTIDE LE CONFORT MEDICAL (BLC.PA) is 6 and the Price/Book (PB) ratio is 1.72.


Can you provide the financial health for BLC stock?

The financial health rating of BASTIDE LE CONFORT MEDICAL (BLC.PA) is 2 / 10.